BioNTech SE/$BNTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About BioNTech SE
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
Ticker
$BNTX
Sector
Primary listing
Employees
6,772
Headquarters
Website
BioNTech SE Metrics
BasicAdvanced
$24B
-
-$1.70
1.24
-
Price and volume
Market cap
$24B
Beta
1.24
52-week high
$129.27
52-week low
$81.20
Average daily volume
1M
Financial strength
Current ratio
8.607
Quick ratio
8.366
Long term debt to equity
1.174
Total debt to equity
1.457
Interest coverage (TTM)
-2.05%
Profitability
EBITDA (TTM)
-585.454
Gross margin (TTM)
79.76%
Net profit margin (TTM)
-11.98%
Operating margin (TTM)
-26.12%
Effective tax rate (TTM)
11.18%
Revenue per employee (TTM)
$509,910
Management effectiveness
Return on assets (TTM)
-2.12%
Return on equity (TTM)
-1.84%
Valuation
Price to revenue (TTM)
6.998
Price to book
1.29
Price to tangible book (TTM)
1.43
Price to free cash flow (TTM)
-7.872
Free cash flow yield (TTM)
-12.70%
Free cash flow per share (TTM)
-12.609
Growth
Revenue change (TTM)
6.98%
Earnings per share change (TTM)
-31.82%
3-year revenue growth (CAGR)
-48.60%
3-year earnings per share growth (CAGR)
-68.32%
What the Analysts think about BioNTech SE
Analyst ratings (Buy, Hold, Sell) for BioNTech SE stock.
Bulls say / Bears say
BioNTech and Duality Biologics achieved Phase 3 trial success for BNT323 (trastuzumab pamirtecan) in inoperable, previously treated HER2-positive breast cancer, meeting the primary PFS endpoint and positioning BioNTech for possible regulatory approval and entry into the high-value HER2 oncology market. (Reuters )
Bristol Myers Squibb agreed to pay $1.5 billion upfront and as much as $11.1 billion in total for rights to co-develop and commercialize BNT327, providing major non-dilutive funding and validation of BioNTech’s bispecific antibody platform. (Reuters )
As of June 30, 2025, BioNTech held €15.99 billion in cash, cash equivalents, and security investments, providing multiyear funding for its diversified oncology pipeline without the need for near-term financing. (Reuters )
BioNTech reported a net loss of €386.6 million for Q2 2025 and a six-month loss of €802.4 million, with the company not expecting to achieve positive net income in 2025, highlighting ongoing unprofitability. (Reuters )
The company’s 2025 revenue guidance of €1.7–2.2 billion is below 2024’s €2.75 billion and the €2.5 billion average analyst forecast, demonstrating declining demand for COVID-19 vaccines and the risk of Pfizer inventory write-downs. (Reuters )
A German court found that Pfizer and BioNTech infringed Moderna’s COVID-19 vaccine patent, which may force them to compensate Moderna and introduces legal uncertainty around vaccine royalties and potential revenue liabilities. (Reuters )
Data summarised monthly by Lightyear AI. Last updated on 6 Sept 2025.
BioNTech SE Financial Performance
Revenues and expenses
BioNTech SE Earnings Performance
Company profitability
BioNTech SE News
AllArticlesVideos
COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says
Market Watch5 days ago
BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy
Benzinga1 week ago
BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial
Reuters1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for BioNTech SE stock?
BioNTech SE (BNTX) has a market cap of $24B as of September 17, 2025.
What is the P/E ratio for BioNTech SE stock?
The price to earnings (P/E) ratio for BioNTech SE (BNTX) stock is 0 as of September 17, 2025.
Does BioNTech SE stock pay dividends?
No, BioNTech SE (BNTX) stock does not pay dividends to its shareholders as of September 17, 2025.
When is the next BioNTech SE dividend payment date?
BioNTech SE (BNTX) stock does not pay dividends to its shareholders.
What is the beta indicator for BioNTech SE?
BioNTech SE (BNTX) has a beta rating of 1.24. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.